Get the Stockscreener App
8.18
8.34%
0.63
Gyre Therapeutics Inc stock is traded at $8.18, with a volume of 104.90K.
It is up +8.34% in the last 24 hours and up +13.14% over the past month.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$7.55
Open:
$7.74
24h Volume:
104.90K
Relative Volume:
0.51
Market Cap:
$787.84M
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
87.49
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
+0.49%
1M Performance:
+13.14%
6M Performance:
-29.12%
1Y Performance:
-28.68%
1-Day Range:
$7.60
$8.20
1-Week Range:
$7.3502
$8.22
52-Week Range:
$6.11
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(619) 949-3681
Address
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Compare GYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
8.18 | 712.99M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
Gyre Therapeutics Inc. Flashes Rebound Signal in Oversold ConditionRisk Management & Consistent Profit Trade Alerts - mustnews.co.kr
Can a trend reversal in Gyre Therapeutics Inc. lead to recoveryTrade Risk Assessment & Growth Focused Entry Point Reports - Newser
Gyre Therapeutics Inc. stock trendline breakdownPortfolio Return Report & Real-Time Buy Zone Alerts - Newser
News impact scoring models applied to Gyre Therapeutics Inc.Portfolio Growth Summary & Community Supported Trade Ideas - Newser
RSI + MACD Show Convergence for Gyre Therapeutics Inc.July 2025 Outlook & Growth Oriented Trade Recommendations - Newser
Analyzing drawdowns of Gyre Therapeutics Inc. with statistical toolsJuly 2025 Breakouts & Verified Entry Point Signals - Newser
How to interpret RSI for Gyre Therapeutics Inc. stock2025 Risk Factors & Expert Approved Momentum Ideas - Newser
What’s the recovery path for long term holders of Gyre Therapeutics Inc.July 2025 Movers & Weekly Chart Analysis and Guides - Newser
Tools to assess Gyre Therapeutics Inc.’s risk profileRate Hike & Safe Entry Point Alerts - Newser
Can Gyre Therapeutics Inc. recover in the next quarterInsider Selling & High Yield Stock Recommendations - Newser
Can you recover from losses in Gyre Therapeutics Inc.Oil Prices & Capital Efficient Trading Techniques - Newser
How moving averages guide Gyre Therapeutics Inc. tradingWeekly Trade Report & Fast Gaining Stock Reports - Newser
Is Gyre Therapeutics Inc. reversing from oversold territoryTrade Volume Summary & Short-Term High Return Ideas - Newser
Is Gyre Therapeutics Inc. meeting your algorithmic filter criteriaPortfolio Value Summary & Risk Managed Investment Signals - Newser
How hedge fund analytics apply to Gyre Therapeutics Inc. stockWeekly Stock Analysis & Safe Capital Investment Plans - Newser
Using Python tools to backtest Gyre Therapeutics Inc. strategies2025 Winners & Losers & AI Driven Stock Reports - Newser
Technical Bounce Expected in Gyre Therapeutics Inc. Next WeekJuly 2025 Institutional & Growth Oriented Trade Recommendations - 선데이타임즈
What makes Gyre Therapeutics Inc. stock price move sharplyJuly 2025 Movers & Community Verified Swing Trade Signals - Newser
Combining price and volume data for Gyre Therapeutics Inc.2025 Big Picture & Free High Return Stock Watch Alerts - Newser
Assessing the Earnings Quality and Shareholder Risks at Gyre Therapeutics (GYRE) - AInvest
Candlestick signals on Gyre Therapeutics Inc. stock todayJuly 2025 Decliners & Target Return Focused Picks - Newser
Understanding Gyre Therapeutics Inc.’s price movement2025 Price Action Summary & Fast Entry Momentum Alerts - Newser
When is the best time to exit Gyre Therapeutics Inc.Sell Signal & Low Drawdown Trading Techniques - Newser
Price momentum metrics for Gyre Therapeutics Inc. explainedWeekly Profit Report & Fast Gain Stock Tips - Newser
How to build a custom watchlist for Gyre Therapeutics Inc.Gold Moves & Growth Focused Stock Pick Reports - Newser
Using RSI to spot recovery in Gyre Therapeutics Inc.Analyst Upgrade & Risk Controlled Daily Trade Plans - Newser
Using AI based signals to follow Gyre Therapeutics Inc.Product Launch & Fast Exit and Entry Strategy Plans - Newser
Can Gyre Therapeutics Inc. be recession proofEarnings Overview Report & Low Risk High Win Rate Stock Picks - thegnnews.com
What Technical Tools Say About Gyre Therapeutics Inc. RecoveryQuarterly Performance Summary & Weekly Top Gainers Alerts - metal.it
Published on: 2025-08-16 06:42:22 - Newser
Is Gyre Therapeutics Inc. a defensive stockPortfolio Risk Summary & Free Real-Time Volume Trigger Notifications - thegnnews.com
How to use a screener to detect Gyre Therapeutics Inc. breakoutsEarnings Risk Report & Detailed Earnings Play Strategies - Newser
Gyre Therapeutics Reports Q2 2025 Earnings and Strategic Updates - TipRanks
Using flow based indicators on Gyre Therapeutics Inc.Swing Trade & Expert Curated Trade Setups - Newser
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gyre Therapeutics Inc Stock (GYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
May 28 '25 |
Sale |
10.07 |
558 |
5,619 |
2,806,084 |
| Ma Songjiang | President |
May 22 '25 |
Sale |
10.97 |
2,000 |
21,940 |
2,808,824 |
| Ma Songjiang | President |
May 23 '25 |
Sale |
10.24 |
182 |
1,864 |
2,808,642 |
| Ma Songjiang | President |
May 20 '25 |
Sale |
11.25 |
2,000 |
22,500 |
2,812,824 |
| Ma Songjiang | President |
May 21 '25 |
Sale |
10.83 |
2,000 |
21,660 |
2,810,824 |
| Ma Songjiang | President |
May 16 '25 |
Sale |
11.31 |
2,000 |
22,620 |
2,816,824 |
| Ma Songjiang | President |
May 19 '25 |
Sale |
11.11 |
2,000 |
22,220 |
2,814,824 |
| Ma Songjiang | President |
May 15 '25 |
Sale |
10.68 |
2,000 |
21,360 |
2,818,824 |
| Ma Songjiang | President |
May 14 '25 |
Sale |
11.30 |
20 |
226 |
2,820,824 |
| Ye Weiguo | Chief Operating Officer |
Apr 01 '25 |
Option Exercise |
0.75 |
50,000 |
37,500 |
700,000 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):